Radiopharm Theranostics Limited American Depositary Shares (RADX)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style analyst: I want a durable business, honest accounting, and a margin of safety. Radiopharm Theranostics is a clinical-stage radiotherapeutics company with a pipeline of diagnostic and therapeutic candidates such as RAD101, RAD102, RAD201a, RAD202, RAD203 and RAD204. From the supplied facts, I cannot see an approved product, revenue, or profit. That means there is no demonstrated moat or earnings power to value. The FairStock calculations show a negative P/E of -0.33 and P/B of 0.82 at the 2026-10-13 close. A price below book value can look cheap, but with ROE of -174.71% and ROCE of -45.15%, the accounting value is being consumed by losses. The balance-sheet risk scores are poor: Piotroski F-Score 0/9 and Altman Z-Score -0.99. The company has a $36.1M market cap, 14 employees, no dividend, and a beta of 0.86. The stock has fallen from a 52-week high of $16.25 to $1.20, near the $1.00 low. No revenue growth or profit growth figures are provided. The Lynch category is none because there are only 0 years of filed results; three are needed. FairStock Score is 37/100. Growth is entirely pipeline-dependent: trial success, regulatory progress, or partnerships could transform the story, but those are future events, not current financial facts. Graham would demand a large discount to tangible value and evidence of staying power. Buffett would want an understandable, durable franchise. I see speculative optionality, not a proven value compounder. The price may be low, but low price alone is not enough; the business must first show it can survive and commercialize its science.

In plain English: Radiopharm Theranostics is a very small clinical-stage company developing radioactive medicines for cancer diagnosis and treatment. It has no profits, weak financial strength signals, and no sales or profit growth figures were provided. The stock trades near its 52-week low and below its accounting value, but without earnings or a long history it is hard to call it a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer